Ticker LaunchReverse merger · Completed · ELVN
Enliven Inc. (Former Enliven)
Reverse merger with IMARA Inc.
Enliven Inc. (Former Enliven) merged into IMARA Inc., a Nasdaq-listed biotech that sold its tovinontrine PDE9 program to Cardurion, in a reverse merger that takes the private company public. The deal was announced on Oct 13, 2022 and closed on Feb 23, 2023. The combined company trades as Enliven Therapeutics, Inc. (ELVN) on Nasdaq.
Enliven Therapeutics is a clinical-stage precision oncology company discovering and developing next-generation small molecule kinase inhibitors. It runs two parallel lead programs and expects cash runway into early 2026 after the merger and private placement.
- Status
- Completed
- Private company
- Enliven Inc. (Former Enliven)
- Public company
- IMARA Inc.
- Public company business before
- Nasdaq-listed biotech that sold its tovinontrine PDE9 program to Cardurion
- Announced
- Oct 13, 2022
- Closed
- Feb 23, 2023
- Combined company
- Enliven Therapeutics, Inc. (ELVN)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Contingent value rights (CVR)
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Mar 1, 2023
- Closing press release
- All filings on EDGAR CIK 1672619
Other completed reverse mergers
- CalciMedica, Inc.into Graybug Vision, Inc. · Mar 22, 2023
- Best Labs, Inc.into Nowtransit Inc · Mar 10, 2023
- Carisma Therapeutics Inc.into Sesen Bio, Inc. · Mar 7, 2023
- Bret Consultores, SAPI de CV: Carbon Captureinto Arma Services Inc · Feb 27, 2023
- Cycle Energy Corp.into American International Holdings Corp. · Feb 15, 2023
- Lithium Harvest ApSinto Sustainable Projects Group Inc. · Feb 15, 2023